Denali Therapeutics and Sanofi have joined efforts to develop small molecule inhibitors of the RIPK1 enzyme, a new class of potential therapeutic agents for a range of neurological and inflammatory diseases, including amyotrophic lateral sclerosis (ALS). The collaboration agreement is focused on the clinical development of two…
Search results for:
News
Protein Clumps That Turn Toxic in ALS Also Found in Healthy Muscle Undergoing Repair, Study Reports
While TDP-43 aggregates are associated with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, researchers have found that these protein clumps are also involved in the regeneration of healthy skeletal muscle. This finding — that abnormal TDP-43 aggregates temporarily form to repair damaged muscle — may open new lines of research into…
In amyotrophic lateral sclerosis (ALS), patients experience progressive muscle weakness and a decline in motor control due to the death of nerve cells in the central nervous system that control the voluntary muscles. This can result in the patient experiencing a range of symptoms, including difficulty walking, muscle…
News
ALS and Fatigue
Amyotrophic lateral sclerosis (ALS) is a progressive disorder of the nervous system, which leads to the death of motor neurons, or nerve cells that control the voluntary muscles. As the disease progresses, many patients experience fatigue, a symptom that can severely affect quality of life. What causes fatigue…
Treatment with a compound called inosine over 12 weeks increased the levels of the antioxidant urate, a neuroprotective agent, in patients with amyotrophic lateral sclerosis (ALS), according to a pilot trial. The investigational therapy also showed a positive safety and tolerability profile, indicating it might have potential as an…
Despite a lack of clinical evidence, complementary and alternative medicines (CAM) are often used by patients with amyotrophic lateral sclerosis (ALS), sometimes in combination with conventional medications, according to a review study. With scarce evidence on the safety and effectiveness of CAM in ALS and the possible risks they…
RNA molecules that are associated with genetic disorders characterized by damage to nerve fibers are found at higher-than-usual numbers in compartments of nerve cells, a new study reports. This finding may lead to new ways of treating neuromuscular diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy and…
Amyotrophic lateral sclerosis (ALS) is a severe progressive neurodegenerative disorder associated with the loss of motor neurons, which transmit signals from the brain to the voluntary muscles to contract. Without these, muscles begin to weaken, leading to a progressive loss of control over movement, speaking, eating, and breathing. There…
Tiglutik, an oral suspension of riluzole, is now available as a treatment for amyotrophic lateral sclerosis (ALS) in the U.S., ITF Pharma, the therapy’s developer and a subsidiary of Italfarmaco, recently announced. Rilutek (riluzole, marketed by Sanofi), has been available in the U.S. as 50 mg tablets…
Researchers have discovered that mast cells and neutrophils — two types of immune cells — are involved in the degeneration of peripheral motor nerve cells and progression of amyotrophic lateral sclerosis (ALS). These findings also clarify why masitinib — an investigational therapy for ALS that targets mast cells…